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doi:10.1016/j.jmii.2012.03.002Background: The seroprevalence and seroincidence of novel influenza A infection among
HIV-infected patients, who were believed to have more severe outcomes than healthy individ-
uals, are rarely investigated in the era of highly active antiretroviral therapy (HAART). Our aim
was to determine the seroprevalence and seroincidence of novel influenza A infection among
HIV-infected patients in Taiwan.
Methods: Between September and November 2009, before the implementation of a nationwide
vaccination for novel influenza A in Taiwan, 931 HIV-infected patients and 566 persons seeking
voluntary counseling and testing (VCT) for HIV infection at our university hospital were
enrolled in this study. Antibody responses to novel influenza A were determined using a hemag-
glutination-inhibition (HI) assay.
Results: HIV-infected patients had a significantly lower seroprevalence of novel influenza A
infection than VCT clients (14.7% vs. 33.9%, p < 0.001). The seroincidence of novel influenza
A infection among HIV-infected patients was 9.4% (95% confidence interval [CI]: 7.6e11.4). On
the multivariate analysis, heterosexual (odds ratio [OR]: 1.89; 95% CI: 1.105e3.227) and base-
line HI titer (OR: 1.02; 95% CI: 1.001e1.038) were significantly associated with seroconversion
to novel influenza A virus.of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of
Taiwan.
tw (S.-Y. Chang).
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152 C.-C. Hung et al.Conclusion: HIV-infected patients demonstrated a lower seroprevalence of novel influenza A
infection than HIV-uninfected patients in Taiwan in the HAART era. Among HIV-infected
patients, seroconversion to novel influenza A virus, which was infrequent during the 2009 influ-
enza epidemic, was associated with heterosexual behavior and baseline HI titer.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
In April 2009, the World Health Organization (WHO) re-
ported that a swine-origin influenza A (H1N1) virus (novel
influenza A virus) was spreading via human-to-human
transmission and had raised serious public concerns
around the world.1 Between April 2009 and March 2010, an
estimated 43e88 million cases were infected in the United
States during this H1N1 pandemic.2 By the end of May 2010,
18,114 deaths from causes related to H1N1 infection had
been reported worldwide; pneumonia was reported as
a contributing cause of death in 7.9% of all deaths reported
in the 122 Cities Mortality Reporting System.2
Although it remains controversial whether novel influ-
enza A is more virulent than seasonal influenza, several risk
factors associated with adverse outcome following novel
influenza A infection have been identified.3e5 In addition,
among individuals who were hospitalized for influenza and
related complications, HIV-infected patients who had
a lower CD4 count were reported to develop more severe
complications to novel influenza A infection, and these
patients often developed secondary bacterial infections
including pneumonia.6 Nevertheless, two recent publica-
tions reported that the clinical presentation and clinical
outcomes of HIV-infected patients who were also infected
with novel influenza A were similar to those of the general
population.7,8
After the identification of the first case of novel influenza
A infection in Taiwan in late May 2009, the novel influenza
A epidemic started in June 2009.9 From June 2009 through
April 2010, a total of 13,931 specimens, mainly from
patients with symptoms of influenza-like illness who sought
healthcare at the hospitals or clinics around Taiwan, were
screened for novel influenza A, and 3274 (23.5%) of these
specimens were confirmed as novel influenza A infection.9 A
nationwide free-of-charge vaccination program for novel
influenza A was implemented in November of 2009 for
individuals at high risk of developing influenza A-related
complications and, in December of 2009 this program was
implemented in healthy adults. As of April 2010, the Taiwan
Centers for Disease Control estimated that 24.5%
(5,667,703/23,133,074) of the people living in Taiwan had
received the novel influenza A vaccine.10
In this study, our aim is to compare the seroprevalence
of novel influenza A virus infection between HIV-infected
patients and persons seeking voluntary counseling and
testing (VCT) for HIV and to examine the seroincidence of
novel influenza A virus infection among HIV-infected
patients who received HIV care, including highly active
antiretroviral therapy (HAART), in Taiwan, where the novel
influenza A epidemic started in June 2009, peaked in late
August and November, and subsided in December 2009.9Methods
Study setting and population
In Taiwan, HIV-related care, including HAART and the
laboratory tests that monitor virological and immunologic
status before or after the initiation of HAART, was intro-
duced in Taiwan in 1997 and is provided free-of-charge to
patients at designated hospitals. As a public health
response to the HIV epidemic, a program that provides
anonymous voluntary counseling and testing (VCT) for HIV
has been in use since 1990.
Between September and November 2009, residual blood
samples were collected from HIV-infected patients who
visited the hospital for the determination of CD4 and
plasma HIV-RNA load (PVL) and from HIV-negative persons
who sought VCT services. The study period spanned 3
months, which is the interval the vast majority of HIV-
infected patients who seek regular HIV care go before
needing to refill their antiretroviral therapy. We included
blood samples from all of the patients who returned to the
hospital to monitor their CD4 count and plasma HIV-RNA
load, which was performed every 3e6 months according to
the DHHS guidelines.11 In this study, we estimated that the
blood samples included in this study were from 60% of all of
the HIV-infected patients who sought HIV care during the
3-month study period.
VCT clients were chosen as a comparator group for this
seroprevalence study because more than 70% of HIV-
infected patients and VCT clients are homosexual males
and they might share similar socioeconomic backgrounds in
the metropolitan area around Taipei. Patients were
excluded from the present study if they had received
a novel influenza A vaccine at the time of enrollment. A
standardized case collection form was used to retrospec-
tively record data on demographics, clinical characteristics,
and laboratory results of the HIV-infected patients. This
study was approved by the institutional review board of the
hospital and all patients gave written informed consent.Laboratory investigations
The antibody response of the serum samples to a novel
influenza A strain, A/California/07/2009, was determined
using a hemagglutination-inhibition (HI) assay, according to
the standard protocols of the World Health Organization
Collaborating Centre for Reference and Research on
Influenza, Melbourne, Australia.12 The receptor-destroying
enzyme (RDE [III], Deka Seiken Co. Ltd, Tokyo, Japan)
was used to treat serum samples that were titrated in
a 2-fold dilution from 1:10 to 1:1280 in order to examine its
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For each serum sample, duplicate experiments were per-
formed. Titers were expressed as the reciprocal of the
highest dilution of serum that prevented hemagglutination.
A Serum HI-antibody titer of  40 was defined as seror-
eactive to novel influenza A. A  4-fold increase in titers, or
conversion from seronegative to HI titers > 40 between
two sequential serological samples from the same indi-
vidual was defined as evidence of novel influenza A
seroconversion.
For those subjects who had elevated HI-antibody titers,
archived blood samples that were collected during or
before the study period were identified and subjected to
the HI assay. The HI titer that was determined was desig-
nated as the baseline HI titer. The baseline specimens from
individuals seeking anonymous HIV screening were identi-
fied by their unique code that consisted of the first letter of
their identification card, birth year, gender, and the last
four digits of their identification card. The interval between
the two blood samples was around 3 months. Those patients
who did not have paired samples for HI-antibody determi-
nation were excluded from the estimation of seroinci-
dence. HI assays were not performed on archived blood
samples from patients who did have elevated HI titers due
to the assumption that they were seronegative.Statistical analysis
All statistical analyses were performed using SPSS software
version 16.0 (SPSS Inc., Chicago, IL, USA). Associations
between categorical variables were analyzed using the c2
test or Fisher’s exact test, whereas the means or medians
of continuous variables were compared using the Student t
test or Mann-Whitney U test. All tests were two-tailed and
a p-value < 0.05 was considered significant. For the
univariate and multivariate analysis, the individuals were
divided into three groups based on their year of birth. The
year 1957 was chosen because according to previous
reports,13,14 individuals born before 1957 might have been
exposed to a strain of H1N1 similar to 1918 strain, which
could induce cross-reactivity to the novel influenza A virus.
The year 1975 was chosen simply to compare results with
a US study,14 in which the authors reported that individuals
born before 1975 might have been exposed to the swine
influenza outbreak that occurred in New Jersey in 1976 and
had cross-reactivity to novel H1N1. The predictors for
antibody response and seroconversion to novel influenza A
were analyzed using linear regression and logistic regres-
sion models. Based on the findings of previous studies, we
assumed that the seroconversion rate of the study pop-
ulation would be 10% and the prevalence would be 30%.15,16
Therefore, we estimated the sample size, n, needed to
make P (estimated rate-true rate > d) < 0.05 using
the formula n  1:962NPð1 PÞ=ðN  1Þd2þ
1:962Pð1 PÞz1:962Pð1 PÞ=d2, where P is the true rate
and N is the total number of patients in the study pop-
ulation. We assumed that N would be large. Thus, we
obtained an estimated sample size of 385 cases for sero-
conversion analysis and 897 cases for seroprevalence anal-
ysis would be required to reach 80% statistical power with
3% error.Results
Clinical characteristics and seroprevalence of
novel influenza A
Between September and November 2009, a total of 1497
patients, including 931 HIV-infected patients and 566 HIV-
uninfected VCT clients, were tested for antibody responses
to novel influenza A infection (Fig. 1). The interval between
the collection of blood samples was the same in both groups
(September 2009 to November 2009). Compared with
HIV-uninfected persons, HIV-infected patients were older
(median age: 37 vs. 27 years, p < 0.001) and were predom-
inately male (94.2% vs. 90.5%, pZ 0.007) (Table 1). Among
HIV-infected patients, 49.2% were born between 1957e1975
and 12.7% were born before 1957, while among HIV-
uninfected individuals, 85.2% were born after 1975. For
HIV-infected patients, the median CD4 cell count and the
percentage of patients with plasma HIV-RNA load < 1.60
log10 copies/mL were 446 cells/mL (range: 3e3,078 cells/mL)
and 56%, respectively (Table 1). When HI assays were per-
formed, almost 75% of HIV-infected patients (74.9%; 697/
931) were receiving HAART with a median duration of 47.2
months (range: 0.03e161.7 months). During the study
period, none of the study patients were hospitalized due to
novel influenza A infection.
Compared with the HIV-uninfected subjects, HIV-
infected patients had a statistically and significantly
lower overall seroprevalence of novel influenza A (14.7% vs.
33.9%, p < 0.001) (Table 1). The seroprevalence of novel
influenza A in each of the two groups of patients are plotted
according to age and month in Figs. 2A and 2B, respectively.
The seroprevalence of novel influenza A was significantly
higher in HIV-uninfected individuals than HIV-infected
patients across all age groups (Fig. 2A). A significant
lower seroprevalence of influenza virus infection was
observed among HIV-1-infected individuals than HIV-1
uninfected individuals in October and November (9.6%
[35/365] vs. 78/191 [40.8%] in October, p < 0.001; 22.9%
[72/314] vs. 76/163 [46.6%] in November, p < 0.001)
(Fig. 2B). On the multivariate logistic analysis, receipt of
HAART (odds ratio [OR]: 2.10; 95% confidence interval [CI]:
1.110e3.955; p Z 0.02), heterosexual behavior (OR: 2.14;
95% CI: 1.335e3.428; pZ 0.002), and baseline HI titer (OR:
1.03; 95% CI: 1.007e1.045; p Z 0.008) were statistically
and significantly associated with an elevated antibody level
to novel influenza A (Supplementary Table 1). Age was not
statistically or significantly associated with an elevated
antibody level to novel influenza A, although a significantly
higher proportion of those who received HAART were
indeed older than those who had not received HAART
(p < 0.001) (data not shown).
Incidence of novel influenza A infection among
HIV-infected patients and contributing factors
Paired serum samples were available from 113 of 137
seroreactive HIV-infected patients (82.5%) that were then
used to determine the seroincidence of novel influenza A
(median interval between collection of the two paired
samples: 6.05 months; range: 2.59e10.61 months), of
Figure 1. Study flow of seroprevalence and seroincidence of novel influenza A infection in HIV-infected and HIV-uninfected
individuals.
Table 1 Clinical characteristics of HIV-infected individuals and HIV-uninfected patients who sought VCT for HIV infection
Characteristics HIV-infected
patients
HIV-uninfected
VCT clients
p
Total screened 931 566
Male gender, n (%) 877 (94.2) 512 (90.5) 0.007
Age (y), median (range) 37 (1e87) 27 (16e60) <0.001
Birth year Before 1957, n (%) 118(12.7) 8(1.4) <0.001
Between 1957e1975, n (%) 458 (49.2) 76 (13.4) <0.001
After 1975, n (%) 355 (38.1) 482 (85.2) <0.001
Risky behavior for HIV infection, n (%) MSM 654 (70.2) 389 (68.7) 0.54
Heterosexual 151 (16.2) 175 (30.9) <0.001
IDU 41 (4.4) 0 (0) <0.001
Others or unknown 85 (9.1) 2 (0.4) <0.001
CD4 cells/mL, median (range) 446 (3e3078) NA d
CD4  200 cells/mL, n/N (%) 811/907 (89.4) NA d
Plasma HIV-1 RNA load 1.60 log10 copies/mL, n/N (%) 507/906 (56.0) NA d
Receipt of HAART, n (%) 697 (74.9) NA d
Duration of HAART (mo), median (range) 47.2 (0.03e161.7) NA d
HI titer  1:40, n (%) 137 (14.7) 192 (33.9) <0.001
Abbreviations: HAART, highly active antiretroviral therapy; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; HI,
hemagglutination-inhibition assay; IDU, injecting drug users; MSM, men who have sex with men; NA, not applicable; VCT, voluntary
counseling and testing.
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Figure 2. (A) Seroprevalence and seroincidence of novel influenza A infection among HIV-infected and HIV-uninfected individ-
uals, according to age (years). Serum samples that were collected from 931 HIV-infected patients (filled triangle) and 566
HIV-uninfected persons (filled square) were tested using a hemagglutination-inhibition (HI) assay. The percentage of subjects with
antibody titers of 40 (defined as having an antibody response to novel influenza A) was plotted according to the age of the
subject. The percentage of HIV-infected subjects (filled bar) and HIV-uninfected persons (open bar) with seroconversion (defined as
having at least a 4-fold increase in an antibody response to novel influenza A or conversion from seronegative to HI titers >40
between 2 sequential serological samples from the same individual) was plotted as bars according to the age of the subjects. (B)
The dynamic of seroprevalence between the HIV-infected and HIV-uninfected patients stratified by month. The percentage of
subjects with antibody titers of 40 (defined as having an antibody response to novel influenza A) was plotted according to the time
of sample recruitment. The percentage of HIV-infected subjects (filled triangle) and HIV-uninfected persons (filled square) with
seroreactivity was plotted.
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incidence of 9.4% (85/907; 95% CI: 7.6e11.4)(Fig. 1). Among
VCT clients, 55 of 192 seroreactive subjects (28.6%) had
paired serum samples available for analysis, of which 44
showed seroconversion, resulting in an estimated incidence
of 10.3% (44/429) (95% CI: 7.6e13.4). There was no statis-
tical or significant difference in terms of the incidence
between the two groups of subjects (p Z 0.60). The range
of the baseline HI titers was the same in both groups
(negative to 1:40). An increase in incidence from 5.0% ofHIV-infected patients aged  21 years to 12.4% of patients
aged  42 years was observed (Fig. 2A), although the trend
of this increase was not statistically significant (p Z 0.32).
All of the HIV-infected patients maintained regular clinic
appointments every 1e3 months during the study period
and no hospitalizations were required due to H1N1 or
respiratory tract infections, as verified by a review of their
medical records.
Using multivariate analysis, we found that only hetero-
sexual behavior (OR: 1.89; 95% CI: 1.105e3.227; p Z 0.02)
Table 2 Multivariate logistic analysis of the predictors of seroconversion to novel influenza A (H1N1) in HIV-1-infected patients
Covariate Estimate Standard error Wald 95% confidence limits Wald Chi-Square p
Intercept 3.0747 0.3317 d 85.9080 <0.0001
Receipt of HAART 0.6203 0.3546 0.928 e 3.726 3.0593 0.0803
Heterosexual 0.6359 0.2733 1.105 e 3.227 5.4140 0.0200
Baseline HI titer 0.0192 0.0093 1.001 e 1.038 4.2403 0.0395
Abbreviations: HAART, highly active antiretroviral therapy; HI, hemagglutination inhibition.
Number of total observations (n) Z 825; percentage of concordant pairs Z 51%; percentage of discordant pairs Z 28.6%; adjusted
generalized R2Z 0.0443; estimated area under the receiver operating characteristic (ROC) curveZ 0.612; and Hosmer and Lemeshow
goodness-of-fit test, p Z 0.3390e0.05 (df Z 5).
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p Z 0.04) were statistically and significantly associated
with seroconversion to novel influenza A among HIV-1-
infected individuals (Table 2).
Discussion
In this study, which was conducted during the 2009
epidemic of novel influenza A infection in Taiwan, we found
that a significantly lower seroprevalence of novel influenza
A infection in HIV-infected patients than HIV-uninfected
subjects. This observation, that the incidence was similar
between HIV-infected patients and HIV-uninfected VCT
clients (85/907 vs. 44/429, p Z 0.60), suggests that our
study groups might have had similar risk of exposure to
novel influenza A during or prior to the epidemic.
The reasons for the lower seroprevalence of HIV-
infected patients may be related to several epidemiologic
and clinical factors. Compared with HIV-infected patients,
more VCT clients are heterosexual and female. On multi-
variate analysis, heterosexuality, receipt of HAART, and
baseline HI titer were associated with seropositivity. It is
possible that heterosexuals are more likely to be exposed
to children with influenza, although we did not perform
interviews to obtain information on clinical symptoms
indicative of influenza, upper respiratory tract infections,
or possible exposure via the family or community. The
immunodeficiency status of the HIV-infected patients may
have also contributed to reduced antibody responses once
exposed to novel influenza A infection, and thus the receipt
of HAART, which has been shown to normalize the memory
B-cell subpopulation that is critical for antibody produc-
tion,17 and also have contributed to seropositivity.
The incidence of novel influenza A infection was low
(9.4%) among HIV-infected patients, which is close to or
lower than that observed in a healthy community cohort
in Singapore (13%) and the estimated incidence (14.5%)
reported in a cross-sectional study, which mainly including
patients accessing healthcare in the United Kingdom.15,16
On the multivariate analysis, baseline HI titer, which was
influenced by age (p Z 0.003), receipt of HAART (p Z
0.01), and homosexual behavior (pZ 0.01) (Supplementary
Table 2) were associated with seroconversion in HIV-
infected individuals. The baseline HI titer most likely
reflects the cross-reactive antibody response induced by
the 1957 influenza epidemic.14 The steadily increasing
trend of seroincidence in older HIV-infected patients could
be boosted by the pre-existing antibody response to the1957 influenza strain, which suggests that, at least among
those > 52 years old, the memory cells that might have
been exposed to the influenza virus antigen before HIV
infection could still be boosted in those receiving HAART.17
There are several limitations to our study, and inter-
pretation of our data should be cautious. First, there are
significant differences in terms of baseline characteristics
between the two study populations. The HIV-infected
patients were older and were more likely to be male.
Since a proportion of elderly persons may have cross-
reactive antibodies to novel influenza A,14 our observa-
tions may be biased. Second, < 30% of the VCT clients who
were seropositive for novel influenza A also provide paired
serum samples for analysis. Therefore, without a sufficient
sample size of sequential blood specimens from HIV-
uninfected subjects available for analysis, the incidence
in the HIV-uninfected population could have been under-
estimated. Third, the incidence of novel influenza A in
HIV-infected patients may have been underestimated
because their immune functions are compromised by HIV
infection. The absence of seroconversion may simply
reflect the incompetence of their immune systems to
mount an antibody response to novel influenza A.
In conclusion, HIV-infected patients who received regular
HIV care at our university hospital had a lower seropreva-
lence of novel influenza A infection than HIV-uninfected
subjects in Taiwan. Among HIV-infected patients, serocon-
version for novel influenza A virus that was infrequent in the
2009 influenza epidemic was associated with heterosexual
behavior and baseline HI titer.Conflicts of interest
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